As seen in Figure 2, the presence of ER+ in the patient’s breast cancer tissue can be treated with tamoxifen therapy, considering that ER+ may place breast cancer cell lines under the type Luminal A, the most prevalent type that also has low levels of Ki-67. This evidence concerns the gene MKI67 and breast carcinoma.